Joel B. Braunstein, MD, MBA
Founder, Chief Executive Officer
Dr. Braunstein co-founded LifeTech Research (LTR) in 2003. He is a board-certified cardiologist and internist. In addition to guiding the vision and strategy of LTR and various of its affiliate companies, he provides analytics in the areas of clinical trial design and methods, outcomes research, and healthcare policy and economics. Through LTR and its affiliates, Dr. Braunstein has played a key operational role in the start-up of numerous life sciences companies. He currently sits on five corporate boards: C2N Diagnostics, a rapidly emerging Alzheimer’s (and other neurodegenerative disorder) diagnostics and biomarker company; Centegen, Inc, a therapeutics company developing novel agents against drug-resistant staphylococci; NexGen Medical Systems and Correx, device companies each developing transformative minimally-invasive surgical and vascular interventional devices; and Tivorsan Pharmaceuticals, a biologics company developing a recombinant protein for a serious genetic disorder.
Dr. Braunstein received his M.D. with highest distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School until 1999, and as a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an M.B.A. with management focus in 2004 and maintained an Assistant Professor cardiology faculty position at Johns Hopkins University. He remains an advisor to the Johns Hopkins Carey School of Business, and is a Distinguished Alumnus of the University. In addition to his various management responsibilities, Dr. Braunstein currently maintains an Adjunct Assistant Professorship at the Yale Center for Outcomes Research and Evaluation (CORE) and the Yale School of Medicine.